George Q. Daley

Dr. George Q. Daley is the Samuel E. Lux, IV Professor of Hematology/Oncology and Director of the Stem Cell Transplantation Program at Boston Children’s Hospital; a Professor of Biological Chemistry and Molecular Pharmacology at Harvard University; and an Investigator at Howard Hughes Medical Institute. Daley is a leader in stem cell research, an author of international guidelines for ethical oversight and clinical translation of stem cells, and a spokesman for stem cell research policy. Over the course of his research career, Daley has pioneered various murine and cell-culture models of leukemia and genetic disorders. He led landmark research using a mouse model to study human chronic myeloid leukemia, contributing data that validated BCR-ABL as a drug target and stimulated the development of the chemotherapeutic Gleevec. He also created patient-specific stem cells for modeling human disease and customized rejection-proof cell therapies. His work was among the first to derive human-induced pluripotent stem cells (iPS), and the first to generate multiple disease-specific iPS cells, which was quoted in Science as the Breakthrough of the Year. Daley is the Past president of the International Society for Stem Cell Research, has testified six times before the U.S. Senate and House on stem cell research policy, and is the recipient of numerous awards including the E. Mead Johnson Award from the Society for Pediatric Research, the NIH Directors Pioneer Award, and the E. Donnall Thomas Prize from the American Society for Hematology.